Recently, we used a tailored nanoemulsion (TNE) to encapsulate tumour antigens for the presentation to the cross‐presenting dendritic cells (DC) through the specific receptor Clec9A (Clec9A‐TNE).7 This evidence concerns the gene CLEC9A and neoplasm.